Q4 2024 Arcadia Biosciences Inc Earnings Call Transcript
Key Points
- Arcadia Biosciences Inc (RKDA) successfully executed a multiyear plan to focus on profitability, exiting underperforming brands and simplifying operations.
- The company monetized a portion of its wheat intellectual property portfolio, providing non-dilutive capital and reducing operating expenses.
- Zola coconut water products experienced significant growth, with revenues increasing 46% year-over-year and distribution expanding by 86%.
- Arcadia's gross margins remained strong, with Zola achieving a gross margin of 33% in 2024, consistent with previous guidance.
- The company reduced its operating cash consumption by 30% in the second half of 2024, aligning with its strategy of profitable growth.
- Arcadia Biosciences Inc (RKDA) reported a decline in gross margin rate from 51% in 2023 to 41% in 2024 due to changes in product sales mix.
- The company incurred $1.2 million in unanticipated transaction-related fees in the second half of 2024, impacting its financial performance.
- Sales of GLA oil declined by 60% in the second half of 2024, and the company has completely sold out of GLA inventory, with no sales expected in 2025.
- Selling, general, and administrative costs increased to $9.6 million in 2024, up from $8.2 million in 2023, partly due to transaction costs.
- Arcadia ended 2024 with a reduced cash balance of $4.2 million, down from $11.6 million at the start of the year, reflecting cash consumption challenges.
Good afternoon, and welcome to Arcadia Biosciences fourth-quarter and full-year 2024 financial results and business highlights conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to Mark Kawakami, Chief Financial Officer at Arcadia. Please go ahead.
Thank you and good afternoon. Joining me on the call today is T.J. Schaefer, Arcadia's President and Chief Executive Officer. This call is being webcast, and you can refer to the company's press release at arcadiabio.com. Before we start, we would like to remind you that Arcadia Biosciences will be making forward-looking statements on this call based on current expectations and currently available information.
However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied today. You can review the company's safe
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
